Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Yun Seob | - |
dc.contributor.author | Cho, Jin Seon | - |
dc.contributor.author | Cho, Kang Su | - |
dc.contributor.author | Doo, Seung Hwan | - |
dc.contributor.author | Chung, Byung Ha | - |
dc.contributor.author | Kim, Se Joong | - |
dc.contributor.author | Yang, Won Jae | - |
dc.contributor.author | Song, Ki Hak | - |
dc.contributor.author | Kim, Chun Il | - |
dc.contributor.author | Hong, Sung Joon | - |
dc.date.accessioned | 2021-08-12T07:34:34Z | - |
dc.date.available | 2021-08-12T07:34:34Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0042-1138 | - |
dc.identifier.issn | 1423-0399 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18568 | - |
dc.description.abstract | Objective: To evaluate the comparative efficacy of adjuvant gemcitabine and cisplatin (GC) chemotherapy between patients with locally advanced transitional cell carcinoma (TCC) of the bladder and upper urinary tract. Patients and Methods: From 2001 to 2005, we retrospectively selected a total of 64 patients with locally advanced TCC of the bladder and upper urinary tract who received at least 3 cycles of adjuvant GC chemotherapy. We compared disease-free and overall survival between the 2 groups. Results: The recurrence rate was 30.3% in TCC of the bladder and 25.8% of the upper urinary tract (p = 0.633). Statistical analysis revealed that there was no significant difference in the disease-free or overall survival rate between TCC of the bladder and upper urinary tract treated with adjuvant GC chemotherapy. Conclusion: Under the circumstances of limited data about TCC of the upper urinary tract, this study may suggest that adjuvant GC chemotherapy in locally advanced TCC of the upper urinary tract is as effective as those of bladder. Copyright (C) 2010 S. Karger AG, Basel | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | S. Karger AG | - |
dc.title | Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.1159/000296294 | - |
dc.identifier.scopusid | 2-s2.0-77955667699 | - |
dc.identifier.wosid | 000280230500008 | - |
dc.identifier.bibliographicCitation | Urologia Internationalis, v.85, no.1, pp 47 - 51 | - |
dc.citation.title | Urologia Internationalis | - |
dc.citation.volume | 85 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 47 | - |
dc.citation.endPage | 51 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | LONG-TERM-SURVIVAL | - |
dc.subject.keywordPlus | PLUS CISPLATIN | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | RADICAL CYSTECTOMY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | VINBLASTINE | - |
dc.subject.keywordPlus | UROTHELIUM | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordAuthor | Transitional cell carcinoma | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Bladder | - |
dc.subject.keywordAuthor | Renal pelvis | - |
dc.subject.keywordAuthor | Ureter | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.